vs
Side-by-side financial comparison of ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) and AC Immune SA (ACIU). Click either name above to swap in a different company.
AC Immune SA is the larger business by last-quarter revenue ($1.4M vs $574.1K, roughly 2.5× ASCENTAGE PHARMA GROUP INTERNATIONAL).
Ascentage Pharma Group International is a global clinical-stage biotechnology company specializing in developing novel targeted therapies for cancers, chronic viral infections, and age-related diseases. It focuses on small molecule drugs targeting apoptosis pathways and other key oncogenic mechanisms, with operations spanning China, the U.S., and other global markets, serving patients with unmet medical needs worldwide.
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.
AAPG vs ACIU — Head-to-Head
Income Statement — Q4 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $574.1K | $1.4M |
| Net Profit | — | $-23.3M |
| Gross Margin | — | — |
| Operating Margin | — | -1484.5% |
| Net Margin | — | -1622.4% |
| Revenue YoY | — | 90.1% |
| Net Profit YoY | — | 6.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $574.1K | — | ||
| Q2 25 | $32.6M | $1.4M | ||
| Q2 24 | — | $755.7K | ||
| Q3 22 | — | $4.3M |
| Q4 25 | — | — | ||
| Q2 25 | $11.4M | $-23.3M | ||
| Q2 24 | — | $-25.0M | ||
| Q3 22 | — | $-14.9M |
| Q4 25 | — | — | ||
| Q2 25 | 90.7% | — | ||
| Q2 24 | — | — | ||
| Q3 22 | — | — |
| Q4 25 | — | — | ||
| Q2 25 | — | -1484.5% | ||
| Q2 24 | — | -3051.1% | ||
| Q3 22 | — | -342.2% |
| Q4 25 | — | — | ||
| Q2 25 | — | -1622.4% | ||
| Q2 24 | — | -3313.0% | ||
| Q3 22 | — | -343.6% |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $28.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $82.2M |
| Total Assets | — | $209.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q2 25 | — | $28.3M | ||
| Q2 24 | — | $56.7M | ||
| Q3 22 | — | $49.0M |
| Q4 25 | — | — | ||
| Q2 25 | — | $82.2M | ||
| Q2 24 | — | $135.8M | ||
| Q3 22 | — | $209.1M |
| Q4 25 | — | — | ||
| Q2 25 | — | $209.2M | ||
| Q2 24 | — | $261.3M | ||
| Q3 22 | — | $226.1M |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
